Antidote Technologies joins forces with Beyond Type 1 and JDRF to launch the first-ever Spanish-language clinical trial search engine for type 1 diabetes (T1D)
Today, Antidote is excited to announce our collaboration with Beyond Type 1 and JDRF to release the first-ever Spanish-language clinical trial search engine for type 1 diabetes (T1D). This groundbreaking version of Antidote Match™ empowers users to search for type 1 diabetes trials in their preferred language, marking a significant step to improve diversity, equity, and inclusion in diabetes research.
The United States is the world’s second-largest Spanish-speaking country, and people of a Hispanic background make up around 18% of the U.S. population — but despite this, less than 8% of all clinical trial participants identify as Hispanic. Additionally, new research suggests that Hispanic American youth are diagnosed with T1D more often than other demographics, which is especially notable given that T1D diagnoses are not as common as those for type 2 diabetes.
Providing these individuals with new and better diabetes treatment options is vital, but that is only possible when the research taking place is reflective of real-world patient populations. Patients and caregivers can now visit BeyondType1.org, JDRF.org, Antidote.me, and other patient advocacy websites that host Antidote Match™ to choose between an English or Spanish version of the journey when searching for T1D clinical trials. By answering a few health-related questions, they can be matched to trials and view results in their preferred language, opening up new opportunities for Spanish-speaking individuals to engage in diabetes research.